Intermediate Capital Group

Recent news, insights, research and analysis Our latest Annual Report and Accounts, to read by section or download in full

Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by ICG

Funds will be used to complete phase 3 clinical development of eneboparatide (AZP-3601) for hypoparathyroidism, and advance AZP-3813 into the clinic for acromegaly

A strong focus on sustainability and people

CEO foreword to Sustainability & People Report 2022

ICG expands into food innovation market with investment in Big Mama Seafood

“Big Mama Seafood is the dominant market leader in the Korean condiment manufacturing market, having enjoyed a first-mover advantage” says ICG’s Wooseok Jun Key findings of US and European private companies analysis by ICG’s Head of Economic and Investment Research Nicholas Brooks The breadth of our firm underpins our ability to invest across the capital structure and create value through cycles Explore our flexible investment strategies and financing solutions

Total assets under management (AUM)